Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Equity Average (2020 - 2025)

Historic Equity Average for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $636.7 million.

  • Relay Therapeutics' Equity Average fell 1625.92% to $636.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $636.7 million, marking a year-over-year decrease of 1625.92%. This contributed to the annual value of $764.9 million for FY2024, which is 1012.95% down from last year.
  • Per Relay Therapeutics' latest filing, its Equity Average stood at $636.7 million for Q3 2025, which was down 1625.92% from $693.4 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Equity Average ranged from a high of $975.0 million in Q4 2022 and a low of $594.8 million during Q3 2021
  • Its 5-year average for Equity Average is $775.4 million, with a median of $760.3 million in 2024.
  • In the last 5 years, Relay Therapeutics' Equity Average skyrocketed by 41591.75% in 2021 and then crashed by 2151.87% in 2023.
  • Relay Therapeutics' Equity Average (Quarter) stood at $734.4 million in 2021, then surged by 32.75% to $975.0 million in 2022, then fell by 21.52% to $765.2 million in 2023, then grew by 5.64% to $808.3 million in 2024, then dropped by 21.23% to $636.7 million in 2025.
  • Its Equity Average stands at $636.7 million for Q3 2025, versus $693.4 million for Q2 2025 and $749.4 million for Q1 2025.